NAPISTAR-301

APGOT-OV22: Open-label, randomized (1:1) phase III study to investigate TUB-040 monotherapy when compared to physician’s choice of therapy in patients with high-grade, serous or endometrioid platinum-resistant ovarian cancer (PROC).

NAPISTAR-3012026-09-16T16:24:01+10:00

BEHOLD-En02

APGOT-EN5: A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan in combination with immune checkpoint inhibition for maintenance treatment of participants with mismatch repair proficient (MMRp) endometrial cancer.

BEHOLD-En022026-10-27T10:11:15+11:00

BEHOLD-En01 | NCT07286331

APGOT-EN4: A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy.

BEHOLD-En01 | NCT072863312026-09-16T16:15:45+10:00

RAINFOL-08 | NCT07564141

APGOT-EN7: A Phase 3 Randomized, Open-Label Study of Rinatabart Sesutecan (Rina-S) Plus Pembrolizumab versus Chemotherapy Plus Pembrolizumab for 1L Treatment of Patients with Primary Advanced or Recurrent pMMR Endometrial Cancer.

RAINFOL-08 | NCT075641412026-10-01T12:49:55+10:00

Symbiotic-GYN-18 | NCT07578649

APGOT-EN6: An interventional phase 3, open label, randomized study to evaluate efficacy and safety of pf-08634404 in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in adult participants with advanced or recurrent mismatch repair proficient endometrial cancer.

Symbiotic-GYN-18 | NCT075786492026-10-27T10:03:12+11:00

RAINFOL-03 | NCT07166094

APGOT-EN3: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer (EC) After Platinum-Based Chemotherapy and PD(L)-1 Therapy.

RAINFOL-03 | NCT071660942026-09-16T15:56:28+10:00

EN.10/TAPER | NCT05640999

The primary objective of this study is to estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status.

EN.10/TAPER | NCT056409992026-06-12T09:36:53+10:00

XPORT-EC-042

XPORT aims to evaluate the benefit of selinexor in patients with no TP53 alteration advanced or recurrent Endometrial Cancer. Patients will receive either oral selinexor or placebo as maintenance therapy following chemotherapy, until disease progression.

XPORT-EC-0422026-06-12T09:37:22+10:00

ENDO-3 | NCT04073706

ENDO-3 is a randomised controlled trial that compares sentinel lymph node dissection, a commonly performed procedure for the surgical staging of endometrial cancer, to no node dissection. The outcomes from this trial will provide high-level evidence on sentinel lymph node [...]

ENDO-3 | NCT040737062026-03-12T21:29:31+11:00
Go to Top